BioStem Technologies to Host First Quarter 2025 Financial Results Conference Call on May 12, 2025

Rhea-AI Summary

BioStem Technologies (OTC: BSEM), a MedTech company specializing in placental-derived biologics for advanced wound care, has scheduled its first quarter 2025 financial results announcement for May 12, 2025.

The company will host a conference call and webcast at 4:30 PM ET, featuring presentations from CEO Jason Matuszewski and CFO Michael Fortunato. Investors can participate through:

• North America Toll-Free: (800) 715-9871
• International Toll: +1 (646) 307-1963
• Conference ID: 9695874

Interested parties can register for the webcast through the provided link and stay updated by joining BioStem's distribution list and following their social media channels on X and LinkedIn.

Positive

• BioStem Technologies maintains OTC market listing status
• Company demonstrates transparency through scheduled earnings call and investor communications

Negative

• None.

Conference call and webcast to be held at 4:30 PM ET

POMPANO BEACH, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces it will release its first quarter 2025 financial results on Monday, May 12, 2025, and will host a conference call and webcast at 4:30 PM ET.

The webcast will feature an overview of the quarter from Jason Matuszewski, CEO, and Michael Fortunato, CFO. To register for the event, please click HERE.

Conference Call & Webcast Information:

• Conference ID:  9695874
• North America Toll-Free: (800) 715-9871
• International Toll: +1 (646) 307-1963
• Webcast Link: https://events.q4inc.com/attendee/970503834

Join BioStem’s Distribution List & Social Media:
To follow the latest developments at BioStem, sign-up to the Company’s email distribution list HERE, and follow us on X and LinkedIn.

About BioStem Technologies, Inc. (OTC: BSEM): BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain ^® processing method. BioREtain ^® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established per current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE ^® , VENDAJE AC ^® , and VENDAJE OPTIC ^® . Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida. For more information visit biostemtechnologies.com and follow us on Twitter and Linkedin.

Forward-Looking Statements: Except for statements of historical fact, this release also contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified using words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate”, “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements with respect to the operations of the Company, strategies, prospects and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: (1) the impact of any changes to the reimbursement levels for the Company’s products; (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause the Company’s products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete;(4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company’s ability to raise funds to expand its business; (6) the Company has incurred significant losses since inception and may incur losses in the future; (7) changes in applicable laws or regulations; (8) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (9) the Company’s ability to maintain production of its products in sufficient quantities to meet demand; and (10) the COVID-19 pandemic and its impact, if any, on the Company’s fiscal condition and results of operations; You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

BioStem Technologies, Inc.
Phone: 954-380-8342
Website: http://www.biostemtechnologies.com
E-Mail: info@biostemtech.com
Twitter: @BSEM_Tech
Facebook: BioStemTechnologies

Investor Relations:
Adam Holdsworth
E-Mail: adam@holdsworthco.com
Phone: 917-497-9287

FAQ

When will BioStem (BSEM) release Q1 2025 earnings?

BioStem (BSEM) will release its first quarter 2025 financial results on Monday, May 12, 2025.

How can I join BioStem's (BSEM) Q1 2025 earnings call?

Investors can join BioStem's Q1 2025 earnings call using Conference ID 9695874, by dialing North America Toll-Free (800) 715-9871 or International +1 (646) 307-1963. A webcast is also available at the provided Q4 events link.

What time is BioStem's (BSEM) Q1 2025 earnings conference call?

BioStem's Q1 2025 earnings conference call and webcast will be held at 4:30 PM ET on May 12, 2025.

Who will present at BioStem's (BSEM) Q1 2025 earnings call?

BioStem's Q1 2025 earnings call will feature CEO Jason Matuszewski and CFO Michael Fortunato presenting an overview of the quarter.

How can investors follow BioStem (BSEM) company updates?

Investors can follow BioStem's updates by signing up for the company's email distribution list and following their X and LinkedIn social media accounts.